Evidence map›Paper›PMID 27994106›Full record

ArticleThe American journal of tropical medicine and hygiene2017

Resistance to First-Line Antituberculosis Drugs in Washington State by Region of Birth and Implications for Latent Tuberculosis Treatment Among Foreign-Born Individuals.

Nathan W Furukawa, Mahri Z Haider, Sheanne J Allen, Sherry L Carlson, Scott W Lindquist

Open access · bronzeAbstract read
In one paragraph

Article in The American journal of tropical medicine and hygiene, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.4field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Nathan W FurukawaDepartment of Medicine, University of Washington, Seattle, Washington.
Mahri Z HaiderHarborview Medical Center, University of Washington, Seattle, Washington.
Sheanne J AllenWashington State Department of Health Tuberculosis Program, Olympia, Washington.
Sherry L CarlsonWashington State Department of Health Tuberculosis Program, Olympia, Washington.
Scott W LindquistWashington State Department of Health Tuberculosis Program, Olympia, Washington.
Washington State Department of Health · USHarborview Medical Center · USUniversity of Washington · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The United States has a low burden of drug resistance among tuberculosis (TB) cases compared with other world regions. TB is increasingly concentrated among foreign-born individuals who have higher rates of drug resistance than U.S.-born individuals. While universal drug susceptibility testing is the standard for detecting active tuberculosis, there are limited guidelines for latent tuberculosis infection (LTBI) treatment based on risk factors for drug resistance. To quantify the variable risk of drug resistance among foreign-born individuals, all TB cases in Washington State between 1994 and 2014 with drug resistance data for isoniazid, rifampin, pyrazinamide, and ethambutol were divided into eight regions of birth. Logistic regression was used to characterize regional differences in resistance patterns. Genotypic cluster and lineage data were compared against drug resistance in a subanalysis. Among 4,298 cases, isoniazid resistance was more common in foreign-born individuals (12.6% versus 4.8%;

Indexed as

Drug Resistance, BacterialAdolescentAdultAgedAged, 80 and overAntitubercular AgentsChildChild, PreschoolEthambutolFemaleHumansInfantInfant, NewbornIsoniazidLatent TuberculosisLogistic ModelsAntitubercular AgentsEthambutolIsoniazidPyrazinamideRifampin

Identifiers

PMID27994106
PMCPMC5361525
OpenAlexW2563117811

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.